Richard Allen

Sep 3, 2024 | opmed.doximity.com | Soubhana Asif |Hailey Roumimper |Matthew Kent |Richard Allen

“You wouldn’t last an hour in the asylum where they raised me.”Taylor Swift’s voice croons in the background as an image of the Prometric testing center appears on my screen. This is only one example of a recent viral TikTok trend where people use audio from Swift’s “Who’s Afraid of Little Old Me?” to post videos and pictures that represent places or experiences they’ve deemed difficult, challenging, or perhaps trauma-inducing.

Sep 3, 2024 | opmed.doximity.com | Matthew Kent |Hailey Roumimper |Richard Allen |Brian B Gilmer

Dialing my grandparents' familiar phone number, I reflected on the enduring significance of these 10 digits. Over the years, my grandparents have instilled in me an appreciation for the sharp wit and intelligence of the elderly. However, I remain troubled by the pervasive assumption in medicine that older individuals invariably suffer from cognitive decline.

Sep 3, 2024 | opmed.doximity.com | Brian B Gilmer |Richard Allen |Joseph Philip Zucchi |Danny Landau

Despite being initially described in 1991, when I exited training about 10 years ago, I had never seen, much less treated, a meniscal root tear. However, I am now certain that it was seeing me. What seemed like a relatively rare or obscure diagnosis is now one of the most commonly performed isolated meniscal repairs in my practice. Unfortunately, recognition outside of the sports medicine and arthroscopic knee subspecialty remains lagging and these tears are often missed or present late.

Sep 3, 2024 | opmed.doximity.com | Richard Allen |Brian B Gilmer |Joseph Philip Zucchi |Danny Landau

Something great has happened. The Federal Trade Commission (FTC) struck down the practice of most non-compete clauses in employment contracts. I believe that this is wonderful news and a long time coming, but many may not like this ruling. I think it really depends upon which side of the fence you are on — are you an employer who wants to keep your employees under your thumb, or are you an employee who would like freedom? I think it is obvious from the phrasing of that question which side I am on.

Sep 3, 2024 | opmed.doximity.com | Joseph Philip Zucchi |Richard Allen |Brian B Gilmer |Danny Landau

Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for glycemic control in Type 2 diabetes and later approved for obesity, have embarked on a remarkable journey of therapeutic expansion. Medications such as semaglutide and tirzepatide are now revealing their versatility in addressing a diverse range of complex health conditions, offering a beacon of hope for improved chronic disease management and patient outcomes.